SILO Silo Pharma rises 557 percent despite reporting a wider than expected Q4 2023 per share loss US Residential Real Estate PreMarketing Listing Strategy Industry Shift Analysis IRHOR Iron Horse latest quarterly earnings filing omits core financial metrics and formal forward guidance